MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$49,890K
EPS
-$1.05
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
42,339
37,617
63,520*
32,167
General and administrative
10,352
8,494
6,105*
6,149
Total operating expenses
52,691
46,111
69,625
38,316
Operating loss
-52,691
-46,111
-69,625*
-38,316
Interest and investment income
2,798
2,791
2,883*
3,338
Net loss
-49,893
-43,320
-66,742*
-34,978
Unrealized loss (gain) on investments
3
-284
-112
226
Total other comprehensive loss (gain)
3
-284
-112*
226
Total comprehensive loss
-49,890
-43,604
-66,855
-34,752
Basic EPS
-1.05
-0.96
-1.738
-0.83
Diluted EPS
-1.05
-0.96
-1.738
-0.83
Basic Average Shares
47,606,857
45,067,658
38,468,781
41,912,905
Diluted Average Shares
47,606,857
45,067,658
38,468,781
41,912,905
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Unrealized loss (gain) on
investments
$3K
(400.00%↑ Y/Y)
Total comprehensive
loss
-$49,890K
(-58.89%↓ Y/Y)
Total other
comprehensive loss (gain)
$3K
(400.00%↑ Y/Y)
Net loss
-$49,893K
(-58.90%↓ Y/Y)
Interest and investment
income
$2,798K
(25.81%↑ Y/Y)
Operating loss
-$52,691K
(-56.71%↓ Y/Y)
Total operating
expenses
$52,691K
(56.71%↑ Y/Y)
Research and development
$42,339K
(52.74%↑ Y/Y)
General and
administrative
$10,352K
(75.37%↑ Y/Y)
Buy us a coffee
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)